https://www.selleckchem.com/products/bms493.html
ncer patients. Increased risk of progression from latent tuberculosis infection (LTBI) to tuberculosis (T disease among people living with HIV (PLWH) prioritizes them for LTBI testing and treatment. Studies comparing the performance of interferon gamma release assays (IGRAs) and the tuberculin skin test (TST) among PLWH are lacking. We used Bayesian latent class analysis to estimate the prevalence of LTBI and diagnostic characteristics of the TST, QuantiFERON Gold In-Tube (QFT), and T.SPOT-TB (TSPOT) among a prospective, multicenter co
Like
Comment
Share
